Answers are grounded in this paper and cite their sources.
INTRODUCTION: The relationship between vitamin D levels and cognition in young patients with schizophrenia remains incompletely understood. We explored the association between serum 25-hydroxy vitamin D concentration and long-term memory (i.e., 30-min delayed recall in the Rey Auditory Verbal Learning Test) in patients with first-episode schizophrenia. The body mass index was measured due to the accumulation of vitamin D in fat. METHODS: Forty-six male participants aged 20.9 ± 2.3 years old with first-episode schizophrenia spectrum disorder were recruited. The median body mass index was 24.1, and 25-hydroxy vitamin D was 39.3 nmol/L. The mean delayed recall was 7.6 ± 3.4 words. Serum 25-hydroxy vitamin D concentration and memory performance were below the normative values for healthy adults. 25-hydroxy vitamin D concentrations and ten clinical variables were included as independent variables, and delayed recall values were included as dependent variables in the multiple regression analysis. RESULTS: Regression analysis revealed a statistically significant link between 25-hydroxy vitamin D concentration, benzodiazepine use, and delayed recall, but not for other clinical variables. CONCLUSION: We found a positive association between 25-hydroxy vitamin D serum concentration and delayed recall in patients with first-episode schizophrenia, supporting a need for interventional study investigating vitamin D supplementation for the cognition of patients with schizophrenia. A negative association between benzodiazepine intake and memory performance calls for attention to minimalize benzodiazepine use.
No takes yet. Share an insight, caveat, or question.
Ihln et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: